NeuroPace Given New 13.00 Price Target at Wells Fargo Company
NPCE Stock | USD 10.60 0.35 3.41% |
About 58% of all Neuropace's shareholders are looking to take a long position. The analysis of overall sentiment of trading Neuropace stock suggests that some investors are interested at this time. The current market sentiment, together with Neuropace's historical and current headlines, can help investors time the market. In addition, many technical investors use Neuropace stock news signals to limit their universe of possible portfolio assets.
Neuropace |
NeuroPace had its target price reduced by Wells Fargo Company from 15.00 to 13.00 in a research note released on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock. Separately, Cantor Fitzgerald reaffirmed an overweight rating and issued a 18.00 target price on shares of NeuroPace in
Read at thelincolnianonline.com
Neuropace Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Neuropace can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Neuropace Fundamental Analysis
We analyze Neuropace's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neuropace using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neuropace based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Neuropace is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Neuropace Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neuropace stock to make a market-neutral strategy. Peer analysis of Neuropace could also be used in its relative valuation, which is a method of valuing Neuropace by comparing valuation metrics with similar companies.
Peers
Neuropace Related Equities
FNA | Paragon 28 | 3.20 | ||||
ANIK | Anika Therapeutics | 3.02 | ||||
LUNG | Pulmonx Corp | 2.38 | ||||
KIDS | Orthopediatrics Corp | 2.32 | ||||
OFIX | Orthofix Medical | 2.09 | ||||
AORT | Artivion | 1.62 | ||||
CNMD | CONMED | 1.20 | ||||
GKOS | Glaukos Corp | 0.67 | ||||
IRMD | Iradimed | 0.65 | ||||
NVRO | Nevro Corp | 0.44 | ||||
CVRX | CVRx | 0.07 | ||||
ITGR | Integer Holdings | 0.21 | ||||
SRDX | SurModics | 0.23 | ||||
ELMD | Electromed | 0.90 |
Complementary Tools for Neuropace Stock analysis
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |